Sökning: onr:"swepub:oai:DiVA.org:umu-157546" >
INTERNATIONAL SURVE...
INTERNATIONAL SURVEY REGARDING USE OF MGMT ANALYSES FOR GLIOMA
-
Malmstrom, A. (författare)
-
Kristenssen, B. Winther (författare)
-
- Henriksson, Roger (författare)
- Umeå universitet,Onkologi
-
visa fler...
-
Soderkvist, P. (författare)
-
visa färre...
-
(creator_code:org_t)
- OXFORD UNIV PRESS INC, 2018
- 2018
- Engelska.
-
Ingår i: Neuro-Oncology. - : OXFORD UNIV PRESS INC. - 1522-8517 .- 1523-5866. ; 20, s. 215-215
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- BACKGROUND: MGMT promotor methylation status is part of glioma diagnostics, supporting clinical decision making. Internationally different methods and cut-off levels are used to determine whether a tumor is methylated or unmethylated. Treatment decisions can be inadequate, when methylation status of the tumor can change due to the analysis and cutoff used. MATERIAL AND METHODS: We conducted an international survey, consisting of 27 questions, to clarify which methods are regularly used in different clinico-pathological settings and why a specific method is selected. We also asked about opinions regarding an international consensus on methods and cut-off levels. RESULTS: The survey was answered by 146 respondents - mainly neuropathologists - from 24 countries. The responses show that MGMT methylation status is determined for all gliomas in 37% of laboratories, while 8% do not perform the analysis. The most commonly used methods are msPCR (37%) and pyrosequencing (34%). The main reasons for choosing a specific method are simplicity (56%), cost-effectiveness (49%) and reproducibility of results (49%). For those using pyrosequencing, the most common number of CpG sites analyzed is four, but varies between 1–3 and more than 16. For 50% of laboratories, the company producing the kit determines which CpG sites should be examined, while 33% select the sites themselves. Selection of cut-off is equally distributed between a cut-off a) published in the literature, b) defined by the lab or c) defined by the company performing the analysis. This cut-off varies between different pathology departments. In one lab tumor is determined as methylated in case of 1 methylated CpG site of 17 analyzed. For others cut-off for methylated varies from 1% to 30%. Some report tumor as unmethylated or weakly versus highly methylated. An international consensus on MGMT methylation method is believed to be of advantage by 66%, while only 20% do not find this necessary. A consensus on a cut-off is warranted by 76%. Most suggest that the consensus method should be msPCR (45%) or pyrosequencing (42%), while 17% suggest next generation sequencing. CONCLUSION: While analysis and use of MGMT methylation status has become routine in the clinico-pathological setting, there is still controversy regarding the best laboratory method and the clinically relevant cut-off level. Most respondents suggest that an international consensus on both method and cut-off should be established.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas